Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis
Identifieur interne : 000909 ( Main/Exploration ); précédent : 000908; suivant : 000910Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis
Auteurs : Berend Arnold Ploeger [Pays-Bas] ; Nicholas H. G. Holford [Nouvelle-Zélande]Source :
- Pharmaceutical Statistics [ 1539-1604 ] ; 2009-07.
English descriptors
- KwdEn :
Abstract
Treatment of a slowly progressive disease, such as Parkinson's and Alzheimer's disease should slow down or even reverse progression of the disease. For estimating the actual treatment effect a clinical trial should allow the time course of treatment effects to be distinguished from those due to natural disease progression. A symptomatic treatment effect has a rapid onset, which will disappear after treatment cessation, whereas disease modifying effects are slow and persistent. Our objective was to compare the power of washout and delayed start designs for distinguishing symptomatic and disease modifying effects using disease progression modelling. The effect of dropout due to worsening disease status on the power was also considered. The change in the Unified Parkinson's Disease Rating Scale score over time was simulated, assuming that a treatment has a combined symptomatic and disease modifying effect. The simulated data were then fitted with the combined effect model and also with alternative models with either symptomatic or disease modifying effects alone. The power was derived from the number of times that the true model was correctly distinguished from the alternative models. Including a washout period in which the subjects are followed up after cessation of treatment substantially increases the power to distinguish different treatment effect types (washout>80%; delayed start<60%). Dropout of 40%–50% during the trial has a small effect on power (7% decrease). Under the assumptions of the simulation we found a clear advantage from using the washout design compared with a delayed start design. Copyright © 2008 John Wiley & Sons, Ltd.
Url:
DOI: 10.1002/pst.355
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis</title><author><name sortKey="Ploeger, Berend Arnold" sort="Ploeger, Berend Arnold" uniqKey="Ploeger B" first="Berend Arnold" last="Ploeger">Berend Arnold Ploeger</name></author><author><name sortKey="Holford, Nicholas H G" sort="Holford, Nicholas H G" uniqKey="Holford N" first="Nicholas H. G." last="Holford">Nicholas H. G. Holford</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:68630D906AE1B9730538B8D4B26F9E81DA484E87</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/pst.355</idno><idno type="url">https://api.istex.fr/document/68630D906AE1B9730538B8D4B26F9E81DA484E87/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000132</idno><idno type="wicri:Area/Main/Curation">000111</idno><idno type="wicri:Area/Main/Exploration">000909</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis</title><author><name sortKey="Ploeger, Berend Arnold" sort="Ploeger, Berend Arnold" uniqKey="Ploeger B" first="Berend Arnold" last="Ploeger">Berend Arnold Ploeger</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>LAP&P Consultants BV, Leiden</wicri:regionArea><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Division of Pharmacology, Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden</wicri:regionArea><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Holford, Nicholas H G" sort="Holford, Nicholas H G" uniqKey="Holford N" first="Nicholas H. G." last="Holford">Nicholas H. G. Holford</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Pharmaceutical Statistics</title><title level="j" type="sub">The Journal of Applied Statistics in the Pharmaceutical Industry</title><title level="j" type="abbrev">Pharmaceut. Statist.</title><idno type="ISSN">1539-1604</idno><idno type="eISSN">1539-1612</idno><imprint><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2009-07">2009-07</date><biblScope unit="volume">8</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="225">225</biblScope><biblScope unit="page" to="238">238</biblScope></imprint><idno type="ISSN">1539-1604</idno></series><idno type="istex">68630D906AE1B9730538B8D4B26F9E81DA484E87</idno><idno type="DOI">10.1002/pst.355</idno><idno type="ArticleID">PST355</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1539-1604</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer's disease</term><term>Parkinson's disease</term><term>delayed start design</term><term>disease progression modelling</term><term>statistical power</term><term>washout design</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Treatment of a slowly progressive disease, such as Parkinson's and Alzheimer's disease should slow down or even reverse progression of the disease. For estimating the actual treatment effect a clinical trial should allow the time course of treatment effects to be distinguished from those due to natural disease progression. A symptomatic treatment effect has a rapid onset, which will disappear after treatment cessation, whereas disease modifying effects are slow and persistent. Our objective was to compare the power of washout and delayed start designs for distinguishing symptomatic and disease modifying effects using disease progression modelling. The effect of dropout due to worsening disease status on the power was also considered. The change in the Unified Parkinson's Disease Rating Scale score over time was simulated, assuming that a treatment has a combined symptomatic and disease modifying effect. The simulated data were then fitted with the combined effect model and also with alternative models with either symptomatic or disease modifying effects alone. The power was derived from the number of times that the true model was correctly distinguished from the alternative models. Including a washout period in which the subjects are followed up after cessation of treatment substantially increases the power to distinguish different treatment effect types (washout>80%; delayed start<60%). Dropout of 40%–50% during the trial has a small effect on power (7% decrease). Under the assumptions of the simulation we found a clear advantage from using the washout design compared with a delayed start design. Copyright © 2008 John Wiley & Sons, Ltd.</div></front></TEI><affiliations><list><country><li>Nouvelle-Zélande</li><li>Pays-Bas</li></country><region><li>Hollande-Méridionale</li></region><settlement><li>Leyde</li></settlement></list><tree><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Ploeger, Berend Arnold" sort="Ploeger, Berend Arnold" uniqKey="Ploeger B" first="Berend Arnold" last="Ploeger">Berend Arnold Ploeger</name></region><name sortKey="Ploeger, Berend Arnold" sort="Ploeger, Berend Arnold" uniqKey="Ploeger B" first="Berend Arnold" last="Ploeger">Berend Arnold Ploeger</name></country><country name="Nouvelle-Zélande"><noRegion><name sortKey="Holford, Nicholas H G" sort="Holford, Nicholas H G" uniqKey="Holford N" first="Nicholas H. G." last="Holford">Nicholas H. G. Holford</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000909 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000909 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:68630D906AE1B9730538B8D4B26F9E81DA484E87
|texte= Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis
}}
| This area was generated with Dilib version V0.6.23. |  |